However, another randomized phase III trial (ASPECT) demonstrated that sitimagene ceradenovec, another adenoviral vector used to deliver the HSV-TK gene, failed to improve survival in newly diagnosed GBM patients (mOS, 16.6 vs. 15.1 months; mPFS, 10.3 vs. 8.9 months), although it increased the time to death or reintervention [156]. The gene discussed is TKT; the disease is glioblastoma.